Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease

Circ Res. 2023 Jan 6;132(1):49-51. doi: 10.1161/CIRCRESAHA.122.322298. Epub 2023 Jan 5.

Authors

Kate Kosmac¹, Ahmed Ismaeel¹, Daniel B Kim-Shapiro², Mary M McDermott³

Affiliations

¹ University of Kentucky Center for Muscle Biology, Lexington (K.K., A.I.).
² Wake Forest University, Winston-Salem, NC (D.B.K.-S.).
³ Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine (M.M.M.).

PMID: 36603062
DOI: 10.1161/CIRCRESAHA.122.322298

No abstract available

Keywords: Editorials; cilostazol; disability; nitric oxide; peripheral artery disease; revascularization; therapeutics.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cyclic GMP
Guanylate Cyclase*
Humans
Nitric Oxide
Peripheral Arterial Disease* / drug therapy
Soluble Guanylyl Cyclase
Vasodilator Agents

Substances

Soluble Guanylyl Cyclase
praliciguat
Guanylate Cyclase
Vasodilator Agents
Nitric Oxide
Cyclic GMP